• +1-646-491-9876
    • +91-20-67278686

    Search

    CD40 Ligand-Pipeline Review H2 2017

    CD40 Ligand-Pipeline Review H2 2017

    • Report Code ID: RW00011060477
    • Category Life Sciences
    • No. of Pages 64
    • Publication Month Sep-17
    • Publisher Name Global Markets Direct
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Pipeline Review, H2 2017

    Summary

    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-CD40 ligand or CD40L is a protein that is primarily expressed on activated T cells and is a member of the TNF superfamily. The CD40-CD40 ligand interaction is crucial to the development of T dependent immune responses. The ligand is expressed on a range of cell types including B cells, granulocytes, macrophages and platelets. T cells expressing CD40L provide signals to B cells that induce proliferation, immunoglobulin class switching, antibody secretion, and rescue from apoptosis at different times during the life of a B cell and also have a role in the development of germinal centres and the survival of memory B cells.

    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) pipeline Target constitutes close to 20 molecules. Out of which approximately 18 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 3, 2 and 13 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Central Nervous System, Infectious Disease and Hematological Disorders which include indications Breast Cancer, Amyotrophic Lateral Sclerosis, Autoimmune Disorders, Graft Versus Host Disease (GVHD), Hepatitis B, Hepatocellular Carcinoma, Lymphoma, Metastatic Melanoma, B-Cell Chronic Lymphocytic Leukemia, Bladder Cancer, Glioblastoma Multiforme (GBM), Human Immunodeficiency Virus (HIV) Infections (AIDS), Human Papillomavirus Infections, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Inflammation, Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Melanoma, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Rheumatoid Arthritis, Sicca Syndrome (Sjogren), Solid Tumor and Systemic Lupus Erythematosus.

    The latest report CD40 Ligand-Pipeline Review, H2 2017, outlays comprehensive information on the CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    -The report provides a snapshot of the global therapeutic landscape for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
    -The report reviews CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    -The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    -The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    -The report reviews key players involved in CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics and enlists all their major and minor projects
    -The report assesses CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
    -The report summarizes all the dormant and discontinued pipeline projects
    -The report reviews latest news and deals related to CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) targeted therapeutics

    Reasons to buy

    -Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    -Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    -Identify and understand the targeted therapy areas and indications for CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)
    -Identify the use of drugs for target identification and drug repurposing
    -Identify potential new clients or partners in the target demographic
    -Develop strategic initiatives by understanding the focus areas of leading companies
    -Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    -Devise corrective measures for pipeline projects by understanding CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG) development landscape
    -Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    Table of Contents 2
    List of Tables 5
    List of Figures 5
    Introduction 6
    Global Markets Direct Report Coverage 6
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Overview 7
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Development 8
    Products under Development by Stage of Development 8
    Products under Development by Therapy Area 9
    Products under Development by Indication 10
    Products under Development by Companies 13
    Products under Development by Universities/Institutes 16
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Therapeutics Assessment 18
    Assessment by Mechanism of Action 18
    Assessment by Route of Administration 20
    Assessment by Molecule Type 22
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Companies Involved in Therapeutics Development 24
    Bristol-Myers Squibb Company 24
    eTheRNA Immunotherapies NV 24
    Juno Therapeutics Inc 25
    MedImmune LLC 25
    Memgen LLC 26
    Multimeric Biotherapeutics Inc 26
    Sanofi 26
    Tessa Therapeutics Pte Ltd 27
    TILT Biotherapeutics Ltd 27
    UCB SA 27
    XL-protein GmbH 28
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Drug Profiles 29
    Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies-Drug Profile 29
    Product Description 29
    Mechanism Of Action 29
    R&D Progress 29
    dapirolizumab pegol-Drug Profile 31
    Product Description 31
    Mechanism Of Action 31
    R&D Progress 31
    Delta-24-RGDOX-Drug Profile 33
    Product Description 33
    Mechanism Of Action 33
    R&D Progress 33
    Dendritic Cell Therapy + TILT-234-Drug Profile 34
    Product Description 34
    Mechanism Of Action 34
    R&D Progress 34
    ECI-006-Drug Profile 35
    Product Description 35
    Mechanism Of Action 35
    R&D Progress 35
    hepatitis B vaccine-Drug Profile 36
    Product Description 36
    Mechanism Of Action 36
    R&D Progress 36
    INX-021-Drug Profile 37
    Product Description 37
    Mechanism Of Action 37
    R&D Progress 37
    ISF-35-Drug Profile 39
    Product Description 39
    Mechanism Of Action 39
    R&D Progress 39
    letolizumab-Drug Profile 41
    Product Description 41
    Mechanism Of Action 41
    R&D Progress 41
    LOAd-700-Drug Profile 42
    Product Description 42
    Mechanism Of Action 42
    R&D Progress 42
    MEDI-4920-Drug Profile 43
    Product Description 43
    Mechanism Of Action 43
    R&D Progress 43
    MegaCD40L-Drug Profile 44
    Product Description 44
    Mechanism Of Action 44
    R&D Progress 44
    NJA-730-Drug Profile 45
    Product Description 45
    Mechanism Of Action 45
    R&D Progress 45
    TDI-28-Drug Profile 46
    Product Description 46
    Mechanism Of Action 46
    R&D Progress 46
    TDI-846-Drug Profile 47
    Product Description 47
    Mechanism Of Action 47
    R&D Progress 47
    TT-16-Drug Profile 48
    Product Description 48
    Mechanism Of Action 48
    R&D Progress 48
    UltraCD40L-Drug Profile 49
    Product Description 49
    Mechanism Of Action 49
    R&D Progress 49
    Vaccine to Target Cancer Testis Antigen, CD80 and CD40L for Breast Cancer-Drug Profile 50
    Product Description 50
    Mechanism Of Action 50
    R&D Progress 50
    Vaccine to Target CD40L and GM-CSF for Oncology-Drug Profile 51
    Product Description 51
    Mechanism Of Action 51
    R&D Progress 51
    XL-050-Drug Profile 53
    Product Description 53
    Mechanism Of Action 53
    R&D Progress 53
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Dormant Products 54
    CD40 Ligand (T Cell Antigen Gp39 or TNF Related Activation Protein or Tumor Necrosis Factor Ligand Superfamily Member 5 or CD154 or CD40LG)-Product Development Milestones 56
    Featured News & Press Releases 56
    Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016) 56
    Nov 17, 2015: Memgen Announces Preclinical Results for ISF35 in Combination with Checkpoint Inhibitors in a Model of Metastatic Melanoma 56
    Dec 19, 2011: ALS Therapy Development Institute Announces Research Agreement With Biogen Idec And UCB To Investigate Role Of CD40L In ALS 57
    Dec 07, 2011: Memgen Announces Upcoming Presentation For ISF35 In Chronic Lymphocytic Leukemia At 2011 ASH Annual Meeting 57
    Jun 21, 2011: Memgen Presents Clinical Results For ISF35 In Chronic Lymphocytic Leukemia At ASCO 2011 58
    Dec 09, 2010: Memgen Announces Clinical And Preclinical Results For ISF35 In Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 58
    Dec 08, 2009: Memgen Announces Positive Data Results Of ISF35 For Chronic Lymphocytic Leukemia 59
    Dec 08, 2009: Memgen's ISF35 Sensitizes Cancer Cells To Chemotherapy 60
    Dec 02, 2009: Memgen Selects Clinical Trial Results Of ISF35 For An Oral Presentation At ASH 2009 Annual Meeting 60
    Dec 01, 2009: Memgen's Clinical Trial Results Of ISF35 For Chronic Lymphocytic Leukemia Selected For Presentation At ASH 2009 Annual Meeting 60
    Jun 08, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61
    Jun 04, 2009: Memgen Reports Positive Results For ISF35 In High-Risk Chronic Lymphocytic Leukemia 61
    Oct 21, 1999: Biogen Announces Halt In Several Trials Of Anti-CD40 Ligand Monoclonal Antibody 61
    Appendix 63
    Methodology 63
    Coverage 63
    Secondary Research 63
    Primary Research 63
    Expert Panel Validation 63
    Contact Us 63
    Disclaimer 64

    List of Tables
    Number of Products under Development by Stage of Development, H2 2017 8
    Number of Products under Development by Therapy Areas, H2 2017 9
    Number of Products under Development by Indications, H2 2017 10
    Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 12
    Number of Products under Development by Companies, H2 2017 13
    Products under Development by Companies, H2 2017 14
    Products under Development by Companies, H2 2017 (Contd..1), H2 2017 15
    Number of Products under Investigation by Universities/Institutes, H2 2017 16
    Products under Investigation by Universities/Institutes, H2 2017 17
    Number of Products by Stage and Mechanism of Actions, H2 2017 19
    Number of Products by Stage and Route of Administration, H2 2017 21
    Number of Products by Stage and Molecule Type, H2 2017 23
    Pipeline by Bristol-Myers Squibb Company, H2 2017 24
    Pipeline by eTheRNA Immunotherapies NV, H2 2017 25
    Pipeline by Juno Therapeutics Inc, H2 2017 25
    Pipeline by MedImmune LLC, H2 2017 26
    Pipeline by Memgen LLC, H2 2017 26
    Pipeline by Multimeric Biotherapeutics Inc, H2 2017 26
    Pipeline by Sanofi, H2 2017 27
    Pipeline by Tessa Therapeutics Pte Ltd, H2 2017 27
    Pipeline by TILT Biotherapeutics Ltd, H2 2017 27
    Pipeline by UCB SA, H2 2017 28
    Pipeline by XL-protein GmbH, H2 2017 28
    Dormant Products, H2 2017 54
    Dormant Products, H2 2017 (Contd..1), H2 2017 55

    List of Figures
    Number of Products under Development by Stage of Development, H2 2017 8
    Number of Products under Development by Therapy Areas, H2 2017 9
    Number of Products under Development by Top 10 Indications, H2 2017 10
    Number of Products by Mechanism of Actions, H2 2017 18
    Number of Products by Stage and Mechanism of Actions, H2 2017 18
    Number of Products by Routes of Administration, H2 2017 20
    Number of Products by Stage and Routes of Administration, H2 2017 20
    Number of Products by Top 10 Molecule Types, H2 2017 22
    Number of Products by Stage and Top 10 Molecule Types, H2 2017 22
    Bristol-Myers Squibb Company
    eTheRNA Immunotherapies NV
    Juno Therapeutics Inc
    MedImmune LLC
    Memgen LLC
    Multimeric Biotherapeutics Inc
    Sanofi
    Tessa Therapeutics Pte Ltd
    TILT Biotherapeutics Ltd
    UCB SA
    XL-protein GmbH

    Request for Sample

    Report Url http://www.reportsweb.com//cd40-ligand-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//cd40-ligand-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//cd40-ligand-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments